Physician profile
Tammy Vu
NPI 1578663167
$529.07
in general payments reported to CMS, 2019-2025
13 companies · $18.31 in 2025
The $18.31 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.69 · 2020: $52.41 · 2021: $89.25 · 2022: $54.15 · 2023: $109 · 2024: $132 · 2025: $18.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $130.41 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $129.37 | 2021-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $62.67 | 2024 | |
| Geistlich Pharma, North America, INC. | $36.78 | 2024 | Geistlich Bio-Gide |
| Coopersurgical, INC. | $31.20 | 2022-2023 | Paragard T 380a |
| Organon LLC | $25.64 | 2023 | Nexplanon |
| Exeltis, USA INC. | $22.50 | 2021 | |
| Heidelberg Engineering, INC. | $18.85 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.17 | 2019 | |
| Myovant Sciences INC. | $14.54 | 2021 | |
| Shield Therapeutics INC | $14.37 | 2023 | Accrufer |
| Scynexis, INC. | $13.67 | 2022 | |
| Roche Diagnostics Corporation | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.